ResearcherUniversity of LiverpoolNo recent work listed
Claire Jenkinson
Matched on OpenAlex author ID A5112002745. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2013: 1 paper · 2014: 1 paper · 2015: 3 papers · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper
Papers 7
- Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. Co-author DOI 10.1016/j.ebiom.2021.103802↗
- Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. Co-author DOI 10.1158/1078-0432.ccr-15-0879↗
- Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. Co-author DOI 10.1016/j.jprot.2014.10.001↗
- Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Co-author DOI 10.1158/1078-0432.ccr-14-0365↗
- Biomarkers for early diagnosis of pancreatic cancer. Co-author DOI 10.1586/17474124.2015.965145↗
- Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Co-author DOI 10.1186/1476-4598-13-114↗
- iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance. First author DOI 10.1038/bjc.2013.150↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Eithne Costello · 7 shared papers, 2013–2022 · strength 0.39
- Paper Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic ca… DOI 10.1016/j.ebiom.2021.103802↗
- Paper Biomarkers for early diagnosis of pancreatic cancer. DOI 10.1586/17474124.2015.965145↗
- Paper Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Asso… DOI 10.1158/1078-0432.ccr-15-0879↗
- William Greenhalf · 6 shared papers, 2013–2022 · strength 0.35
- Paper Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic ca… DOI 10.1016/j.ebiom.2021.103802↗
- Paper Biomarkers for early diagnosis of pancreatic cancer. DOI 10.1586/17474124.2015.965145↗
- Paper Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Asso… DOI 10.1158/1078-0432.ccr-15-0879↗
- Stephen P. Pereira · 4 shared papers, 2015–2022 · strength 0.26
- Paper Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic ca… DOI 10.1016/j.ebiom.2021.103802↗
- Paper Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Asso… DOI 10.1158/1078-0432.ccr-15-0879↗
- Paper Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cance… DOI 10.1016/j.jprot.2014.10.001↗
- John F. Timms · 4 shared papers, 2015–2022 · strength 0.26
- Paper Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic ca… DOI 10.1016/j.ebiom.2021.103802↗
- Paper Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Asso… DOI 10.1158/1078-0432.ccr-15-0879↗
- Paper Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cance… DOI 10.1016/j.jprot.2014.10.001↗
- Christopher Michael Halloran · 3 shared papers, 2014–2022 · strength 0.23
- Paper Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic ca… DOI 10.1016/j.ebiom.2021.103802↗
- Paper Biomarkers for early diagnosis of pancreatic cancer. DOI 10.1586/17474124.2015.965145↗
- Paper Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. DOI 10.1186/1476-4598-13-114↗
- John P. Neoptolemos · 5 shared papers, 2013–2016 · strength 0.21
- Paper Biomarkers for early diagnosis of pancreatic cancer. DOI 10.1586/17474124.2015.965145↗
- Paper Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Asso… DOI 10.1158/1078-0432.ccr-15-0879↗
- Paper Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cance… DOI 10.1016/j.jprot.2014.10.001↗
- Paula Ghaneh · 2 shared papers, 2015–2022 · strength 0.19
- Lucy S. Oldfield · 2 shared papers, 2016–2022 · strength 0.18
- Paper Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic ca… DOI 10.1016/j.ebiom.2021.103802↗
- Paper Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Asso… DOI 10.1158/1078-0432.ccr-15-0879↗
- Darragh Patrick O'Brien · 2 shared papers, 2015–2016 · strength 0.08
- Paper Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Asso… DOI 10.1158/1078-0432.ccr-15-0879↗
- Paper Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early… DOI 10.1158/1078-0432.ccr-14-0365↗
- Victoria E. Shaw · 2 shared papers, 2013–2014 · strength 0.07
- Alfredo Carrato · 1 shared paper, 2015 · strength 0.05
- Julie Earl · 1 shared paper, 2015 · strength 0.05
- David Arthur Tuveson · 1 shared paper, 2016 · strength 0.04
- Alexey A. Zaikin · 1 shared paper, 2015 · strength 0.04
- Ross C. Smith · 1 shared paper, 2015 · strength 0.04
- Oleg B. Blyuss · 1 shared paper, 2015 · strength 0.04
- Sarah Tonack · 1 shared paper, 2013 · strength 0.03
- Christoph W. Michalski · 1 shared paper, 2013 · strength 0.03
- Helmut Friess · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.